Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Glenmark Pharmaceuticals Ltd. indicates a positive outlook on the stock, suggesting that investors may consider adding or holding the stock in their portfolios. This rating reflects a balanced assessment of the company’s quality, valuation, financial trend, and technical indicators. It is important to note that the rating was adjusted from 'Strong Buy' to 'Buy' on 01 June 2026, with the Mojo Score decreasing from 81 to 71. However, the current evaluation as of 11 June 2026 confirms that Glenmark remains a fundamentally sound investment opportunity within the Pharmaceuticals & Biotechnology sector.
Here’s How Glenmark Pharmaceuticals Looks Today
As of 11 June 2026, Glenmark Pharmaceuticals is classified as a midcap company with a Mojo Grade of 'Buy' and a Mojo Score of 71.0. The stock has experienced a modest day change of +0.15%, reflecting relative stability in the short term. Over various time frames, the stock’s returns show a mixed but generally positive trend: a 1-year return of +31.34%, a 6-month gain of +9.76%, and a year-to-date increase of +5.48%. These figures demonstrate the company’s resilience and growth potential amid market fluctuations.
Quality Assessment
Glenmark’s quality grade is rated as 'good', underscoring the company’s robust operational and financial health. A key highlight is its strong ability to service debt, with a low Debt to EBITDA ratio of just 0.13 times. This indicates prudent financial management and a low risk of leverage-related distress. Additionally, Glenmark has delivered positive results for the last three consecutive quarters, signalling consistent profitability and operational efficiency. The company’s return on capital employed (ROCE) for the half-year stands at an impressive 40.16%, reflecting effective utilisation of capital to generate earnings.
Valuation Perspective
The valuation grade for Glenmark is deemed 'attractive'. The company’s price-to-book value ratio is 5.8, which, while seemingly elevated, is actually trading at a discount relative to its peers’ historical valuations. This suggests that the stock is reasonably priced given its growth prospects and profitability metrics. The return on equity (ROE) of 26.9% further supports the stock’s attractive valuation, indicating strong shareholder returns. Moreover, the company’s price-to-earnings-to-growth (PEG) ratio is a low 0.2, signalling that the stock’s price growth is well supported by its earnings growth, which has surged by 125.6% over the past year.
Financial Trend and Performance
Financially, Glenmark is on a positive trajectory. The latest data as of 11 June 2026 shows net sales for the nine months at ₹13,718.08 crores, growing at a robust rate of 36.13%. Profit after tax (PAT) for the latest six months reached ₹1,133.97 crores, marking an exceptional growth of 103.40%. These figures highlight the company’s strong revenue generation and profitability momentum. Institutional investors hold a significant stake of 39.67%, reflecting confidence from knowledgeable market participants who typically conduct thorough fundamental analysis before investing.
Technical Outlook
From a technical standpoint, Glenmark’s grade is 'mildly bullish'. This suggests that while the stock shows positive momentum and potential for further gains, it may not be exhibiting strong breakout signals at present. The stock’s recent performance includes a 1-month decline of -8.63% and a 3-month dip of -5.50%, indicating some short-term volatility. However, the longer-term returns and fundamentals provide a solid foundation for investors considering a medium to long-term horizon.
Investor Implications
For investors, the 'Buy' rating from MarketsMOJO implies that Glenmark Pharmaceuticals Ltd. is a stock with favourable fundamentals and valuation metrics, supported by positive financial trends and a stable technical outlook. The company’s strong profitability, low leverage, and attractive valuation make it a compelling option within the Pharmaceuticals & Biotechnology sector. While short-term price fluctuations may occur, the overall outlook suggests potential for capital appreciation and steady returns.
Summary of Key Metrics as of 11 June 2026
- Mojo Score: 71.0 (Buy Grade)
- Debt to EBITDA Ratio: 0.13 times (Low leverage)
- ROCE (Half Year): 40.16%
- ROE: 26.9%
- Price to Book Value: 5.8 (Attractive valuation)
- PEG Ratio: 0.2 (Indicates undervaluation relative to growth)
- Net Sales (9M): ₹13,718.08 crores (+36.13%)
- PAT (6 months): ₹1,133.97 crores (+103.40%)
- Institutional Holdings: 39.67%
- 1-Year Stock Return: +31.34%
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Positioning Within the Market
Glenmark Pharmaceuticals Ltd. stands among the highest 1% of companies rated by MarketsMOJO across a universe of over 4,000 stocks. This elite positioning reflects the company’s strong fundamentals and consistent performance relative to its peers. The pharmaceutical sector continues to be a vital component of the Indian economy, driven by innovation, exports, and domestic demand. Glenmark’s solid financial health and growth trajectory position it well to capitalise on these sectoral tailwinds.
Conclusion
In conclusion, Glenmark Pharmaceuticals Ltd.’s current 'Buy' rating by MarketsMOJO, effective since 01 June 2026, is supported by a comprehensive evaluation of quality, valuation, financial trends, and technical factors as of 11 June 2026. The company’s strong profitability, attractive valuation metrics, and positive financial momentum make it a noteworthy stock for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. While the rating is slightly more conservative than the previous 'Strong Buy', it still signals confidence in Glenmark’s ability to deliver value over the medium to long term.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
